The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the treatment of generalized myasthenia gravis.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Saturday Night Live monologue was almost very different, he said, because show boss Lorne Michaels—and the network censor— ...

UN Watch is calling on Secretary of State Marco Rubio to sanction and deny entry and visa access to UN Special Rapporteur ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

The debate in Philadelphia over a recent report from the Anti-Defamation League reflects a national conversation happening this week in the Senate.

The total number of reported incidents of antisemitism in San Diego County rose by 28%, from 108 in 2023 to 139 in 2024, the ...

California Governor Gavin Newsom and the Israel lobby have enlisted another partner in the frenzy to promote Holocaust ...

Dublin’s goal, according to Israel’s ambassador to Ireland, has been to undermine the Jewish state’s ability to defend itself ...

Leaders from Indiana Jewish organizations gathered with ADL staff last week at the Jewish Community Center of Indianapolis to ...

The number of antisemitic incidents in the San Diego region nearly quadrupled over the last five years, an ADL report has found.